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Abstract
Background: In endothelial cells (EC), transforming growth factor-β (TGF-β) can bind to and
transduce signals through ALK1 and ALK5. The TGF-β/ALK5 and TGF-β/ALK1 pathways have
opposite effects on EC behaviour. Besides differential receptor binding, the duration of TGF-β
signaling is an important specificity determinant for signaling responses. TGF-β/ALK1-induced
Smad1/5 phosphorylation in ECs occurs transiently.
Results: The temporal activation of TGF-β-induced Smad1/5 phosphorylation in ECs was found to
be affected by de novo protein synthesis, and ALK1 and Smad5 expression levels determined signal
strength of TGF-β/ALK1 signaling pathway. Smad7 and protein phosphatase 1α (PP1α) mRNA
expression levels were found to be specifically upregulated by TGF-β/ALK1. Ectopic expression of
Smad7 or PP1α potently inhibited TGF-β/ALK1-induced Smad1/5 phosphorylation in ECs.
Conversely, siRNA-mediated knockdown of Smad7 or PP1α enhanced TGF-β/ALK1-induced
signaling responses. PP1α interacted with ALK1 and this association was further potentiated by
Smad7. Dephosphorylation of the ALK1, immunoprecipitated from cell lysates, was attenuated by
a specific PP1 inhibitor.
Conclusion: Our results suggest that upon its induction by the TGF-β/ALK1 pathway, Smad7 may
recruit PP1α to ALK1, and thereby control TGF-β/ALK1-induced Smad1/5 phosphorylation.
Background
Transforming growth factor-β (TGF-β) elicits its cellular
effects through activation of type I and type II serine/thre-
onine kinase receptors [1,2]. The constitutively active type
II receptor phosphorylates specific serine and threonine
residues in the juxtamembrane region (so-called GS
domain) of the type I receptor. Type I receptor acts down-
stream of type II receptor (Tβ R-II) and has been shown to
determine signaling specificity within the heteromeric
receptor complex. In most cell types, TGF-β signals via
TGF-β type I receptor (Tβ R-I), also termed activin recep-
tor-like kinase 5 (ALK5). In endothelial cells (ECs), how-
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ever, TGF-β can signal via Tβ R-II and two different type I
receptors, i.e. the broadly expressed ALK5 and the EC-
restricted ALK1. Whereas ALK5 inhibits EC migration and
proliferation, ALK1 stimulates both these processes [3].
The activated type I receptor propagates the signal through
phosphorylation of specific receptor-regulated Smads (R-
Smads). Whereas ALK5 induces the phosphorylation of
Smad2 and Smad3, ALK1 mediates the activation of
Smad1 and Smad5 [4,5]. Activated R-Smads can assemble
into heteromeric complexes with common partner (Co-)
Smad, i.e. Smad4 and translocate into the nucleus where
they regulate the transcription of target genes [1,2].
I-Smads (Smad6 and Smad7) are natural inhibitors of
TGF-β signaling that prevent the activation of R- and Co-
Smads [6-8]. They do so by interacting efficiently with the
activated type I receptors preventing access and phospho-
rylation of R-Smads by the activated type I receptors.
Smad6 has also been found to exert its inhibitory effect on
signaling by competing with Smad4 for heteromeric com-
plex formation with activated Smad1 [9] and by recruiting
the co-repressor CtBP and thereby repress transcription
[10,11]. I-Smads were found to interact with Smad ubiq-
uitination-related factors, Smurfs, which are HECT-
domain ubiquitin ligases that target the TGF-β receptors
for degradation [12,13]. The expression of I-Smads is
quickly induced upon stimulation by members of the
TGF-β family and upon shear stress of the endothelium
[14,15]. Thus, I-Smads may be part of negative feedback
control mechanisms.
A key event in TGF-β signaling is serine phosphorylation
of Tβ R-I by Tβ R-II, and of R-Smads by Tβ R-I. These phos-
phorylations are tightly controlled, e.g. the immunophilin
FKBP-12 binds to Tβ R-I and thereby inhibits phosphor-
ylation of Tβ R-I by Tβ R-II [16]. C-terminal phosphoryla-
tion of Smad2 and Smad3 is strongly facilitated by Smad
anchor for receptor activation (SARA)[17].
Serine/threonine protein phosphatases (PPs) are likely
involved in the dephosphorylation of these phosphor-
ylated signaling components. PPs consist of a catalytic
subunit that binds to one or two regulatory subunits that
generate holoenzymes with unique localizations and spe-
cificities [18]. One of the major PPs is PP1 consisting of a
PP1 catalytic subunit (PP1c) that can form complexes
with more than 50 regulatory subunits [19]. Four mam-
malian isoforms of the PP1c gene have thus far been
described, i.e. PP1α, PP1β and two splice variants of PP1γ.
Studies in Drosophila melanogaster suggest that PP1 binds
to the decapentaplegic (dpp) type I receptor with the aid
of SARA and negatively regulates dpp signaling [20]. Very
recently, it was reported that the TGF-β- induced Smad7
can interact with the growth arrest and DNA damage pro-
tein 34 (GADD34) (21), which is a regulatory subunit of
PP1. The Smad7- GADD34 complex was shown to recruit
PP1c to Tβ R-I, and thereby dephosphorylate and inacti-
vate it [22].
In the present report, we have investigated the molecular
mechanisms that underlie the TGF-β-induced transient
ALK1-mediated Smad1/5 phosphorylation versus sus-
tained ALK5-mediated Smad2 phosphorylation in ECs.
Analysis of the effect of various chemical inhibitors on the
TGF-β/ALK1 response, suggested an important contribu-
tion of PP1 in the negative regulation of ALK1 signaling,
but not ALK5 signaling in ECs. Our data suggest that
Smad7, induced by ALK1 activation, recruits PP1α to
ALK1 and thereby inhibits TGF-β/ALK1-induced Smad1/5
phosphorylation in ECs.
Results
Negative regulation of TGF-β-induced Smad1/5 
phosphorylation is dependent on protein synthesis in ECs
Recently we showed that upon TGF-β stimulation in pri-
mary ECs, Smad2 phosphorylation is stable for at least 6
hours whereas Smad1/5 phosphorylation is transient and
absent 3 h after stimulation [3]. In order to find out if this
short duration of TGF-β-induced Smad1/5 activation is
dependent on induction of newly synthesized proteins,
we treated bovine aortic endothelial cells (BAECs) with
the protein synthesis inhibitor, cyclohexamide, and exam-
ined the kinetics of Smad phosphorylation after TGF-β
stimulation. In the non-treated cells, Smad1/5 phosphor-
ylation reached peak levels after 45 min of TGF-β stimula-
tion and declined thereafter until no phosphorylation was
detected after 3 h (Fig. 1A, first panel). Compared to con-
trol cells, the TGF-β-induced Smad1/5 phosphorylation in
cyclohexamide-treated cells was more sustained and
lasted at least 4 h (Fig. 1A, second panel). Total Smad lev-
els were not found to be significantly affected upon
cycloheximide treatment during the course of the experi-
ment. Similar results were obtained in another type of
ECs, the mouse embryonic ECs (MEECs) (Fig. 1C). These
results suggest that the TGF-β induced Smad1/5 signaling
is inhibited by newly synthesized inhibitory proteins.
Signal strength of TGF-β/ALK1 pathway in ECs is critically 
dependent on ALK1 and Smad5 expression levels
Previously, we showed that TGF-β-induced Smad1/5
phosphorylation is dependent on ALK1. Treatment of ECs
with ALK1 antisense oligonucleotides specifically inhib-
ited TGF-β-induced Smad1/5 phosphorylation [3]. To
examine whether intensity and/or duration of signaling is
affected by ALK1 and/or Smad5 levels, we initially
infected BAECs with adenoviral constructs of wtALK1 or
LacZ and analysed TGF-β/Smad phosphorylation. As
shown in Figure 2A, whereas Smad1/5 phosporylation
had returned to background levels after 90 min of TGF-β
stimulation in LacZ infected cells, in cells infected withBMC Cell Biology 2006, 7:16 http://www.biomedcentral.com/1471-2121/7/16
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wild-type (wt) ALK1 adenoviral construct TGF-β-induced
Smad1/5 phosphorylation lasted until 3 h.
We strengthened these data by making use of the BRE-luc
reporter, which can be used as a transcriptional read-out
for TGF-β/ALK1 signaling [3]. TGF-β induction of the
BRE-luc reporter was potentiated upon ALK1 and/or
Smad5 co-transfection (Fig. 2B) and attenuated upon
siRNA-mediated knockdown of ALK1 (Fig. 2C) or Smad5
(Fig. 2D). Inhibition of TGF-β-induced activation of BRE-
luc reporter by siRNA-ALK1 could be rescued by cotrans-
fection of human ALK1 or Smad5, respectively (Fig. 2C,
Negative regulation of TGF-β-induced Smad1/5 phosphorylation Figure 1
Negative regulation of TGF-β-induced Smad1/5 phosphorylation.(A) First panel. BAECs were stimulated with TGF-β 
(1 ng/ml) for different time periods at 37°C before lysis. Whole cell lysate was sonicated and fractionated by SDS-PAGE and 
blotted. The filters were incubated with PS1 antibody that specifically recognizes phosphorylated Smad1/5, PS2 antibody, which 
specifically recognizes phosphorylated Smad2, and antisera against Smad5. The blots were incubated with an actin antibody as a 
control for protein loading. Second panel. BAECs were treated with the protein synthesis inhibitor cyclohexamide (10 ng/ml) 30 
minutes before they were stimulated with TGF-β. The filters were incubated with PS1, PS2 or actin antibodies. Third panel. 
BAECs were treated with the proteasome inhibitor, MG-132 (10 nM), for 30 min before they were stimulated with TGF-β. 
The filters were incubated with PS1, PS2 or actin antibodies. Last panel. BAECs were pre-treated with a phosphatase inhibitor, 
sodium orthovanadate (1 mM) 30 min prior to stimulation with TGF-β following the same procedure as in Fig. 1A. The filters 
were incubated with PS1, PS2 or actin antibody. (B) BAECs were pre-treated (right panel) or not (left panel) with the Ser/Thr 
phosphatase inhibitor calyculin (1 nM) 30 min prior to stimulation with TGF-β for different time periods before lysis. The filters 
were incubated with PS1 or actin antibody. (C) MEECs were pre-treated with cyclohexamide, MG-132, vanadate or not, and 
then stimulated with TGF-β for different time periods as in Fig. 1A.
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D). Taken together, these results demonstrate that TGF-β/
ALK1-induced Smad1/5 activation is critically dependent
on the ALK1 and Smad5 expression level in ECs.
Smad7 is induced upon TGF-β/ALK1 signaling in ECs
The inhibitory Smad7 is known to be upregulated by TGF-
β [8]. Our data imply that the negative regulation of TGF-
ALK1 and Smad are critically important in Smad1/5 phosphorylation in ECs Figure 2
ALK1 and Smad are critically important in Smad1/5 phosphorylation in ECs. (A) BAECs were adenovirally infected 
with wild-type ALK1/HA or LacZ construct at MOI of 1000. Fresh medium containing 10% FBS was added 16 h after infection. 
Eight hours later, the cells were starved overnight and then stimulated with TGF-β (1 ng/ml) for the indicated time periods and 
TGF-β-induced Smad1/5 phosphorylation was measured. Cells were lysed, sonicated and fractionated by SDS-PAGE. The gels 
were then subjected to immunoblotting. The filters were incubated with PS1, PS2, HA or actin antibody. (B) MEECs were 
transfected with BRE-luc in the absence or presence of ALK1 or Smad5, or both. After 48 h, cells were extensively washed. 
Then, cells were stimulated for 8 h with TGF-β, or not, and luciferase activity was measured. Values are corrected for transfec-
tion efficiency as measured by β-galactosidase activity. A representative experiment using triplicate samples is shown. (C) 
MEECs were transfected with (BRE)-luc in the absence or presence of ALK1-RNAi. After 48 h, cells were extensively washed. 
Then, cells were stimulated for 8 h with TGF-β, or not, and luciferase activity was measured. The luciferase activity upon 
RNAi-mediated knockdown of endogenous mouse ALK1 was rescued by co-transfecting a human ALK1 expression plasmid. 
Values are corrected for transfection efficiency as measured by β-galactosidase activity. A representative experiment using trip-
licate samples is shown. (D) MEECs were transfected with BRE-luc in the absence or presence of Smad5-RNAi. After 48 h, cells 
were extensively washed. Then, cells were stimulated for 16 h with TGF-β, or not, and luciferase activity was measured. The 
luciferase activity upon RNAi-mediated knockdown of endogenous mouse Smad5 was rescued by co-transfecting a mouse 
Smad5 plasmid. Values are corrected for transfection efficiency as measured by β-galactosidase activity. A representative 
experiment using triplicate samples is shown.
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β-induced Smad1/5 signaling needs newly synthesized
protein to become effective and Smad7 may thus possibly
mediate this effect. We therefore examined Smad7 expres-
sion levels in ECs by semi-quantitative RT-PCR upon
infection of adenovirus expressing constitutively active
(ca)ALK1, caALK5, or noninfected cells that were stimu-
lated with TGF-β. Fig. 3A shows that Smad7 mRNA was
upregulated upon stimulation of cells with caALK1 and
TGF-β (0.25 ng/ml), and peaked at 30 min to 1 hour of
TGF-β stimulation (data not shown). This bell-shaped
dose-response curve is consistent with a previous observa-
tion that TGF-β-induced Smad1/5 phosphorylation is
most prominent at 0.5–1 ng/ml with higher doses of TGF-
β having less Smad1/5 activation [3]. Notably, caALK5 did
not induce Smad7 expression.
Smad7 is a highly efficient negative regulator of TGF-β/
ALK1 signaling in ECs
Next, we investigated whether overexpression of Smad7
affects TGF-β/ALK1 signaling. The cells were infected with
adenovirus expressing either lacZ or Flag-Smad7 at the
MOI of 1000 and the effect on Smad phosphorylation was
analysed after subjecting the cells to different concentra-
tions of TGF-β. Smad7 overexpression blocked both
Smad1/5 and Smad2 phosphorylation (Fig. 3B, left panel).
Interestingly, if cells were infected with F-Smad7 at a MOI
of 400, resulting in cells with lower levels of ectopically
expressed Smad7 protein, the ALK1/Smad1/5 pathway
but not the ALK5/Smad2 pathway was inhibited (Fig. 3B,
right panel). We also examined whether Smad7 can inhibit
Smad-mediated transcriptional responses in ECs. Smad7
inhibited TGF-β/ALK1-induced BRE-luc activity in a dose
dependent manner (Fig. 3C). TGF-β-induced Smad1/5
phosphorylation was also examined when endogenous
Smad7 expression was specifically inhibited. This was
done by stable transfection in MEEC with siRNA-Smad7
plasmid including a hygromycin cassette. TGF-β-induced
Smad1/5 phosphorylation was found to be prolonged in
MEECs stably transfected with siRNA-Smad7 compared to
control (PGK-hygromycin transfected) cells (Fig. 3D).
Consistent with this finding, upon siRNA-mediated
knockdown of Smad7, TGF-β-induced BRE-luc reporter
activation was significantly enhanced. siRNA-mediated
knockdown of Smad7 moderately inhibited TGF-β/ALK5
signaling using (CAGA)12-luc as read-out (Fig. 3E, right
panel). The latter effect is likely indirectly caused by
increased TGF-β/ALK1 signaling that antagonizes ALK5
signaling [4]. Taken together, these data indicate that
Smad7 is enhanced by TGF-β/ALK1 signaling and that it is
highly effective in inhibiting the same pathway.
Inhibition of proteasome and protein phosphatase activity 
prolongs the TGF-β-induced Smad1/5 phosphorylation in 
ECs
To examine the involvement of the proteasome pathway
in negative regulation of TGF-β/ALK1 signaling we treated
BAECs with the proteasome inhibitor MG-132, and
observed that Smad1/5 phosphorylation was stronger and
prolonged compared to the non-treated cells (Fig. 1A,
third panel). Interestingly, when we treated BAECs with the
serine/threonine phosphatase inhibitor, calyculin,
Smad1/5 phosphorylation was sustained (Fig. 1B). We
also treated the BAECs with the phosphatase inhibitor,
orthovanadate for 30 min. TGF-β-induced Smad1/5 phos-
phorylation was stronger and prolonged compared to
non-treated cells (Fig. 1A, fourth panel). Orthovanadate is
frequently used as a tyrosine phosphatase inhibitor, but
certain PPs, such as the PP1 serine/threonine phos-
phatase, are also potently inhibited by orthovanadate
[23]. These findings suggest that proteasome degradation
and dephosphorylation by PPs play prominent roles in
inhibiting the activation of TGF-β-induced Smad1/5
phosphorylation. As the involvement of proteasome
pathway, but not PPs, had been intensely investigated in
TGF-β signaling, we focused our subsequent studies on
the involvement of PPs in TGF-β/ALK1 signaling.
PP1α, which is transcriptionally induced by ALK1 
activation, negatively regulates ALK1 signaling in ECs
Based upon our results implicating PPs in the negative
regulation of TGF-β-induced ALK1/Smad1/5 phosphor-
ylation in ECs and a previous report about the involve-
ment of PP1 in dephosphorylation of the dpp  type I
receptor [20], we decided to look further into the connec-
tion of PP1 in TGF-β/ALK1 signaling. PP1 isoforms were
expressed at the mRNA level in MEECs using specific sets
of primers (data not shown, see Material and Methods).
The effect of ALK1 or ALK5 activation on PP1 expression
was investigated. Figure 4A demonstrates that only PP1α
is strongly upregulated in MEECs expressing caALK1.
PP1α mRNA was found to be upregulated upon caALK1
expression. Subsequently, we analysed the effect of TGF-β
on P1α expression in time (Fig. 4A); PP1α was already
upregulated after 30 minutes of TGF-β stimulation. Anal-
ysis of Id1, a direct target gene of ALK1 signaling, was
taken along as a control. These data suggest that like
Smad7, PP1α is a direct ALK1 target. However, analysis of
the effect of TGF-β on PP1α protein expression did not
reveal any upregulation (data not shown). The signifi-
cance of PP1α in negative regulation of TGF-β-induced
Smad1/5 activation was shown by siRNA-mediated
knockdown studies of PP1α (Fig. 4B). TGF-β/ALK1-
induced transcriptional activity downstream of the BRE-
luc reporter was greatly enhanced upon specific inhibition
of PP1α expression (Fig. 4C, left panel). Basal PP1 levels
(and cooperating basal Smad7 levels, see below) are notBMC Cell Biology 2006, 7:16 http://www.biomedcentral.com/1471-2121/7/16
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Smad7 is a potent inhibitor of ALK1-induced Smad1/5 phosphorylation in Ecs Figure 3
Smad7 is a potent inhibitor of ALK1-induced Smad1/5 phosphorylation in Ecs.(A) MEECs were stimulated with 
TGF-β or adenovirally infected at MOI of 500 with LacZ, caALK1, caALK5 and Smad7 (included as a positive control). Forty 
hours later, the noninfected cells were starved overnight and then stimulated with TGF-β, or not, for 90 min. Cells were lysed, 
and RNA was isolated and cDNA prepared. Expression of Smad7 was analysed by semi-quantitative RT-PCR. β-actin expres-
sion was measured to control for equal loading. The PCR products were loaded on 1% agarose gel and stained with ethidium 
bromide. (B) Left panel. BAECs were infected with adenoviral constructs of Flag-Smad7 or lacZ as a control with MOI of 1000. 
Forty hours later, BAECs were stimulated with a different dose of TGF-β at 37°C before lysis. Whole cell lysate was sonicated 
and fractionated by SDS-PAGE and blotted. The filters were incubated with PS1, PS2 or α-Flag antibody. Right panel. Differen-
tial Smad7 inhibition on TGF-β induced Smad1/5 phosphoylation and Smad2 phosphorylation in BAECs. BAECs were infected 
with adenoviral constructs of Flag-Smad7, or LacZ as a control, with MOI of 400. Forty hours after infection, BAECs were 
stimulated with 1 ng/ml of TGF-β for different time periods at 37°C before lysis. Whole cell lysate was sonicated and fraction-
ated by SDS-PAGE and blotted. The filters were incubated with PS1, PS2 and Flag antibodies. (C) MEECs were co-transfected 
with caALK1 and BRE-luc with or without Smad7 at different concentrations. Luciferase activity was measured 48 h after trans-
fection. Values are corrected for transfection efficiency as measured by β-galactosidase activity. A representative experiment 
using triplicate samples is shown. (D) Smad7-RNAi plasmid with a hygromycin cassette was stably transfected in MEECs and 
selected on hygromycin medium for 7 days. PGK-hygromycin selected cells were used as mock cells. The cells were serum-
starved overnight and stimulated with TGF-β (1 ng/ml) at different time periods prior to lysis, sonication and fractionation by 
SDS-PAGE. Gels were then subjected to immunoblotting. The filters were incubated with PS1, PS2, or actin antibody. (E) Left 
panel. MEECs were transfected with BRE-luc in the absence or presence of Smad7-RNAi. Forty-eight hours after transfection 
the cells were washed extensively. Luciferase activity was measured after 8 hours of stimulation of TGF-β or not. Values are 
corrected for transfection efficiency as measured by β-galactosidase activity. A representative experiment using triplicate sam-
ples is shown. Right panel. MEECs were transfected with (CAGA)12-luc in the absence or presence of Smad7-RNAi. Forty-eight 
hours after transfection the cells were stimulated for 16 hours with TGF-β and luciferase activity measured. A representative 
experiment using triplicate samples, corrected for transfection efficiency, is shown.
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ALK1-induced PP1α negatively regulates transcriptional activity downstream of TGF-β/ALK1 Figure 4
ALK1-induced PP1α negatively regulates transcriptional activity downstream of TGF-β/ALK1.(A) TGF-β kinetics 
and upregulation of PP1 isoforms on mRNA level. MEECs were stimulated with TGF-β or adenovirally infected with LacZ, 
caALK1, caALK5 or Smad7 at MOI of 500. Forty hours later, including starvation overnight, the cells were lysed, RNA was iso-
lated and cDNA was prepared. PCR-amplified products for PP1α, β and γ and Id1 are indicated on the right of the figure. β-
actin was included as a loading control. (B) MEECs were transfected with siRNA-PP1α using oligofectamine in medium without 
serum. Twelve hours later the transfection medium was changed to medium with 10% FCS. Forty-eight hours later, the cells 
were lysed. Whole cell lysate was sonicated, fractionated on SDS-PAGE and subjected to immunoblotting. The filter was incu-
bated with antibodies against PP1α and actin to measure loading of proteins in each sample. (C) Left panel. MEECs were trans-
fected with BRE-luc in the absence or presence of PP1α. Sixteen hours later the cells (where indicated) were transfected with 
siRNA-PP1α using oligofectamine. Forty-eight hours later, luciferase activity was measured 6 h after stimulation with TGF-β or 
not. Values are corrected for transfection efficiency as measured by β-galactosidase activity. A representative experiment using 
triplicate samples is shown. Right panel. MEECs were transfected with (CAGA)12-luc in the absence or presence of PP1α. After 
16 h, the cells was transfected with siRNA-PP1α (where indicated) using oligofectamine. Thirty-two hours later, cells were 
incubated with TGF-β for an additional 16 h, whereafter luciferase activity was measured. Values are corrected for transfection 
efficiency as measured by β-galactosidase activity. A representative experiment using triplicate samples is shown.
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sufficiently high for TGF-β/Smad1/5 signaling not to ini-
tially proceed. Conversely, transcriptional activity down-
stream of ALK5 was not affected by PP1α knockdown (Fig
4C, right panel). The latter is consistent with our finding
that TGF-β/ALK5 -induced Smad2 phosphorylation (com-
pared to Smad1/5 phosphorylation) is sustained in ECs.
PP1α binds strongly to ALK1 in the presence of Smad7 and 
dephosphorylates the ALK1 kinase
Subsequently, we examined whether PP1α could interact
with ALK1. We co-expressed wild-type (wt) ALK1/HA and
eGFP-PP1α with or without Flag-Smad7 in COS-7 cells.
Cell lysates were subjected to immunoprecipitation for
wtALK1/HA followed by immunoblotting for PP1 (Fig.
5A). PP1α was found to interact with ALK1, and Smad7
further enhanced this interaction. Consistent with these
results, 125I-TGF-β cross-linked to ALK1 was co-immuno-
precipitated with eGFP-PP1α when ALK1 and eGFP-PP1α
were ectopically expressed in 293T cells (data not shown).
Next, we analysed if endogenous PP1 affected the phos-
phorylation of ALK1. MEECs were adenovirally infected
with caALK1/HA and the whole lysate was immunopre-
cipitated with HA antibodies. The samples were washed
and subjected to an in vitro kinase assay followed by a
phosphatase assay in the absence or presence of a specific
PP1 inhibitor, Inhibitor-2 (I-2). As shown in Figure 5B,
ALK1 was phosphorylated in the presence of I-2, whereas
no ALK1 phosphorylation was evident in the absence of I-
2. Taken together, these results indicate that PP1α inter-
acts with and dephosphorylates ALK1.
Discussion
In the present study we have investigated the molecular
mechanisms that underlie the transient Smad1/5 activa-
tion by TGF-β/ALK1 signaling versus the sustained TGF-β/
ALK5-induced Smad2 activation in ECs [3]. Our results
support a model in which the inhibitory Smad7 is specif-
ically induced by the TGF-β/ALK1 pathway and partici-
pates in a negative feedback loop in ECs. A rate equation
model for the TGF-β/Smad pathway in ECs showed that
Smad7 feedback loop provides robustness to the system
[24]. Smad7, previously shown to be capable of interact-
ing with type I receptors [6,8], may recruit PP1α to ALK1.
The serine phosphatase activity of PP1α mediates dephos-
phorylation and inactivation of ALK1.
Duration of TGF-β/Smad signaling is a critical determi-
nant for regulating specificity of cellular biological
responses [2]. During Xenopus embryogenesis differences
in the duration of Smad signaling is carefully controlled
Smad7 recruits PP1α to ALK1 Figure 5
Smad7 recruits PP1α to ALK1. (A) COS-7 cells were transfected with eGFP-PP1α, wtALK1/HA and/or Flag-Smad7. After 
48 h at 37°C, cells were lysed. Whole cell lysates were immunoprecipitatedwith HA antibody, fractionated by SDS-PAGE, and 
subjected to immunoblotting with PP1c antiserum. Total lysates were fractionated by SDS-PAGE and subjected to immunob-
lotting with antisera against Flag, PP1 and HA to check expression levels. (B) Left panel. Phosphatase inhibition assay. MEECs 
were adenovirally infected with the indicated constructs and immunopreciptated with HA antibody. Kinase assay was per-
formed with 2.5 µCi of [32P]γ ATP per sample at 30°C for 30 min. Samples were washed in lysis buffer before they were incu-
bated in a phosphatase buffer with or without the PP1 inhibitor, I-2 at 37°C for 60 min. The samples were separated by SDS-
PAGE and phosphorylation quantified using phosphoimager. Right panel. Fraction of the total lysate was immunoblotted with 
HA antiserum to check expression levels of the receptor.
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since it is important for cell fate decisions [25]. Whereas
epithelial cells with a sustained Smad response are
arrested in growth by TGF-β, pancreatic tumors that dem-
onstrate a transient TGF-β/Smad response have specifi-
cally evaded anti-proliferative effects of TGF-β, while
maintaining other TGF-β responses [26]. TGF-β/ALK1 sig-
naling promotes the activation states of ECs. A transient
versus sustained ALK1 response, as determined by Smad7
and PP1α expression levels, could be of critical impor-
tance for angiogenesis. After ECs receive a TGF-β/ALK1
signal and start to proliferate, migrate and form sprouts,
this signal must be turned off, whereafter the TGF-β/ALK5
signal dominates and the maturation of vessels is
induced. Interestingly, PP1 (and 2A) activity was previ-
ously shown to be needed to maintain ECs in a resting
state [27]; inhibition of PP1c activity promoted EC migra-
tion consistent with a negative role for this phosphatase in
TGF-β/ALK1-induced activation of ECs.
Here we show that in ECs Smad7 is more efficiently
induced by ALK1 than by ALK5. In addition, Smad7 is
more efficient in blocking signaling via ALK1 than ALK5.
Previously, Smad7 was shown to be induced by, and to be
a general inhibitor of, TGF-β superfamily signaling in var-
ious non-ECs [14,28,29]. Specific factors present in ECs
are likely to be the reason why Smad7 is much more
important feedback inhibitor downstream of ALK1 than
ALK5 signaling in ECs, compared to TGF-β and BMP sign-
aling in other cell types.
The proposed mechanism by which PP1 mediates the
dephosphorylation of ALK1 in ECs is reminiscent to that
recently reported for the recruitment of PP1 by Smad7 to
ALK5 in epithelial cells [22]. Shi and co-workers reported
that Smad7 interacts with GADD34, a regulatory subunit
of PP1 holoenzyme. PP1c is recruited to ALK5 via a
Smad7-GADD34 complex and then dephosphorylates
activated ALK5. SARA enhances the recruitment of PP1c to
the Smad7-GADD34 complex by enhancing the availabil-
ity of PP1c to the Smad7-GADD34 complex. Which regu-
latory subunit of PP1α holoenzyme cooperates with
Smad7 to interact with ALK1 remains to be investigated.
Conclusion
Our results suggest that upon its induction by the TGF-β/
ALK1 pathway, Smad7 recruits PP1α to ALK1, and thereby
inhibit TGF-β/ALK1-induced Smad1/5 phosphorylation.
Smad7 functions in different ways to exert its antagonistic
effects. Besides the recruitment of PP1 by Smad7 to the
phosphorylated type I receptor to dephosphorylate and
inactivate it, Smad7 has been shown to compete with R-
Smads for binding to activated type I receptors and
thereby inhibit phosphorylation of R-Smads [6,8]. Our
results do not exclude the possibility that ALK1/Smad sig-
naling is subject to this type of inhibitory regulation by
Smad7. In addition, Smad7 can recruit Smurf E3-ubiqui-
tin ligases to the activated type I receptor, resulting in
receptor ubiquitination and degradation [12,13]. Treat-
ment of ECs with proteasome inhibitor revealed that TGF-
β/ALK1 signaling is also negatively regulated by the pro-
teasome pathway (Fig. 1); whether this occurs at receptor
or Smad level remains to be elucidated. Further experi-
ments are needed to examine the contribution of PP1
compared to other mechanisms of negative control by
Smad7 in TGF-β/ALK1 signaling.
Methods
Ligands, antibodies and inhibitors
Recombinant TGF-β 3 was obtained from K. Iwata (OSI
Pharmaceuticals). Phospho-Smad1/5 and phospho-
Smad2 antibodies that specifically recognize phosphor-
ylated Smad1/5 and phosphorylated Smad2 have been
previously described [3,30], Smad5 rabbit antisera [31],
Flag antibodies (SIGMA), HA antibodies (Roche), α-actin
antibodies (Chemicon), goat-PP1α (Santa Cruz) and
mouse-PP1c antibodies (Santa Cruz), were used in immu-
noblotting. Cells were pre-treated prior to stimulation
with TGF-β and during the stimulation with cyclohexam-
ide (SIGMA), MG-132 (Calbiochem), sodium orthovana-
date (SIGMA-Aldrich) or calyculin (Calbiochem). In the
phosphatase inhibition assay, a human recombinant pro-
tein phosphatase Inhibitor-2 (I-2) (Calbiochem), was
added.
Expression plasmids and RNAi
Constructs for TGF-β signaling components have been
described previously (Goumans et al., 2002). Rabbit
peGFP-C1 PP1α[32] was used in transient transfections.
RNAi -Smad7 was made by cloning 5'-
gatccccGACTCGCGTGGGGAGGCTCttcaagaga-
GAGCCTCCCCACGCGAGTCtttttggaaa-'3 and comple-
mentary oligonucleotides derived from mouse Smad7 in
pSuper, RNAi-ALK1 was made by cloning 5'
gatccccCACGGCTCCCTCTATGACTttcaagagaAGTCATA-
GAGGGAGCCGTGtttttggaaa-'3 and complementary oli-
gonucleotides derived from mouse ALK1 in pSuper and
RNAi-Smad5 was made by cloning 5'-
gatccccGGTGTTCATCTATACTACGttcaagagaCCGTAG-
TATAGATGAACACCtttttggaaa-'3 and complementary oli-
gonucleotides derived from mouse Smad5 in pSuper [33].
To silence endogenous PP1α expression, double-stranded
21-nt RNAs directed against Smad7 were chemically syn-
thesized and purified (Qiagen). The siRNA-PP1α
sequence was 5'-AAGACGUUCACUGACUGCUUC-'3.
Cell culture
Bovine aortic ECs (BAEC) were routinely cultured in low-
glucose DMEM (Gibco BRL) supplemented with 10% calf
serum, L-glutamine and antibiotics. The cells were grown
in a 10% CO2-containing atmosphere at 37°C. MouseBMC Cell Biology 2006, 7:16 http://www.biomedcentral.com/1471-2121/7/16
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embryonic ECs (MEECs) were routinely cultured in
DMEM supplemented with 10% fetal calf serum (FCS),
non-essential amino acids, L-glutamine and penicillin/
streptomycin on 0.1% gelatin-coated dishes. COS-7 and
293T cells were cultured in DMEM supplemented with
10% FCS, L-glutamine and penicillin/streptomycin.
MEECs, COS-7 and 293T cells were grown in 5% CO2-
containing atmosphere at 37°C.
Transfections and transcriptional reporter assays
MEECs were transiently and stably transfected using lipo-
fectamine™ reagent (Invitrogen) according to the manu-
facturer's protocol. COS-7 and 293T cells were transfected
by conventional calcium phosphate co-precipitation
method. In case of siRNA, the transfection was performed
using oligofectamine™ reagent (Invitrogen) according to
manufacturer's instructions. Reporter assays were per-
formed as previously described [34]. MEECs were trans-
fected with 0.5 µg BRE-luc [35] and 0.5 µg (CAGA)12-luc
[36], in the absence or presence of an expression plasmid.
In case of BRE-luc reporter, cells were stimulated with
TGF-β for 6–8 h whereas (CAGA)12-luc transfected cells
were stimulated for 16 h.
Adenoviral infection of ECs
ECs were infected with adenoviruses expressing LacZ,
wtALK1, caALK1, caALK5, Id1 and Smad7 at a multiplica-
tion of infection (MOI) of 500 unless else is indicated.
After 16 h the cells were washed and allowed to recover for
8 h prior to starvation overnight before the indicated
assays.
Western blot analysis and immunoprecipitation
ECs were grown to 90% confluence. Cells were rinsed
with PBS and grown in 0.5% FBS containing medium.
After 16 h, cells were stimulated for 1 h with 10 ng/ml of
TGF-β 3, put on ice, rinsed with PBS and lysed in lysis
buffer (125 mM NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM
EDTA, 1 mM PMSF, 1.5% aprotinin and 1% Triton X-
100). Cell lysates were separated by SDS-PAGE using 8%
polyacrylamide gels, followed by wet-transfer of the pro-
teins to Hybond-C extra nitrocellulose membranes
(Amersham). Non-specific binding of proteins to the
membrane was blocked in TBS-T (0.01 M Tris-HCl, pH
7.4, 0.15 M NaCl, 0.1% Tween-20) containing 3% dry
milk. Primary antibodies were diluted 1000-fold in TBS-T
and secondary horseradish peroxidase-conjugated goat
anti-rabbit or mouse IgG antibody (Amersham) was used
at a 10,000-fold dilution in TBS-T. Detection was per-
formed by ECL. To detect heteromeric complex formation
between Smad7 and PP1α, cell lysates from transfected
COS-7 and MEECs were subjected to immunoprecipita-
tion followed by Western blotting, as previously described
[34].
RNA isolation and reverse transcription polymerase chain 
reaction (RT-PCR)
Total RNA was isolated from MEECs using RNeasy col-
umns (Qiagen) according to manufacturer's instructions.
RT-PCR reactions were performed as described by Gou-
mans et al. (3). The PCR reactions were performed using a
PTC-200 Peltier thermal cycler (MJ Research). The DNA
sequences of the PCR primers that were used are available
on request.
Phosphatase assay
Cells were infected with the indicated viruses. After lysis,
immunoprecipitation was performed using anti-HA anti-
bodies, followed by in vitro kinase assay as described by
Itoh et al. [37] using kinase buffer (40 mM Hepes, pH 7.4,
40 mM MgCl2, 2 mM MnCl2, 2 mM DTT) including 2.5
µCi of [32P]γ ATP, and an incubation time of 30 min. Sam-
ples were washed with lysis buffer before they were sub-
jected to phosphatase buffer (50 mM Tris, [pH 7.5], 1 mM
EDTA, 0.1% β-mercaptoethanol, 1 mg/ml BSA) and incu-
bated with or without Inhibitor-2 (Calbiochem) (10 ng/
ml) at 37°C for 1 h. Protein samples were separated by
SDS-PAGE using 8% polyacrylamide gels, followed by fix-
ation and detection on a phosphoImager.
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